



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: DIAMANDIS et al. Examiner: Unknown
Serial No.: 10/510,321 Group Art Unit: 1645
Filed: May 25, 2005 Docket: 11757.0104USWO
Confirmation No.: 6886 Notice of Allow. Date: N/A

Title: METHODS FOR DETECTING OVARIAN CANCER

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on March 6, 2006.

By: 

Name: Sarah Dannecker

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

23552

PATENT TRADEMARK OFFICE

Commissioner:

We are transmitting herewith the attached:

- ☒ Transmittal Sheet in duplicate containing Certificate of Mailing
- ☒ Supplemental Information Disclosure Statement, Form 1449, 31 Reference(s)
- ☒ Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.


Merchant & Gould P.C.
P.O. Box 2903
Minneapolis, MN 55402-0903
612.332.5300

By: 

Name: Mark T. Skoog

Reg. No.: 40,178

MTS/sbd



Serial No. 10/510,321

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: DIAMANDIS et al. Examiner: Unknown
Serial No.: 10/510,321 Group Art Unit: 1645
Filed: May 25, 2005 Docket No.: 11757.0104USWO
Title: METHODS FOR DETECTING OVARIAN CANCER

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on March 16, 2006.

By: 

Name: Sarah Dannecker

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Commissioner:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. § 1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked

as being considered and initialed by the Examiner, to the undersigned with the next official communication.


Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.



Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Dated: March 6, 2006

By: 
Mark T. Skoog
Reg. No. 40,178

MTS/sbd

FORM 1449*

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

11757.0104USWO

Application Number:

10/510,321

Applicant: DIAMANDIS et al.

Filing Date: May 25, 2005

Group Art Unit: 1645



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	JP 10-133615	11/1999	Japan			Abstract	
	JP 8-056367	11/1996	Japan			Abstract	
	WO 99/09138	02/1999	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Chen et al., "Expression and Activity-Dependent Changes of a Novel Limbic-Serine Protease Gene in the Hippocampus", The Journal of Neuroscience (1995); 15(7): 5088-5097
	Christensson et al., "Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors", European Journal of Biochemistry (1990); 194: 755-763
	Christopoulos et al., "Enzymatically Amplified Time-Resolved Fluorescence Immunoassay with Terbium Chelates", Analytical Chemistry (1992); 64(4): 342-346
	Diamandis et al., "Human Kallikrein 11: A New Biomarker of Prostate and Ovarian Carcinoma", Cancer Research (2002); 62: 295-300
	Diamandis et al., "Human tissue kallikrein gene family: a rich source of novel disease biomarkers", Expert Reviews in Molecular Diagnosis (2001); 1(2): 182-190
	Diamandis et al., "New Nomenclature for the Human Tissue Kallikrein Gene Family", Clinical Chemistry (2000); 46(11): 1855-1858
	Diamandis et al., "The New Human Kallikrein Gene Family: Implications in Carcinogenesis", TEM (2000); 11(2): 54-60
	Diamandis et al., "Human Kallikrein 6 (Zyme/Protease M/Neurosin): A New Serum Biomarker of Ovarian Carcinoma", Clinical Biochemistry (2000); 33(7): 579-583
	Ferguson et al., "Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers", Clinical Chemistry (1996); 42(5): 675-684
	Hassapoglidou et al., "Quantification of p53 protein in tumor cell lines, breast tissue extracts and serum with time-resolved immunofluorometry", Oncogene (1993); 8: 1501-1509

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11757.0104USWO	Application Number: 10/510,321
	Applicant: DIAMANDIS et al.	
	Filing Date: May 25, 2005	Group Art Unit: 1645

	Kishi et al., "Crystal Structure of Neuropsin, a Hippocampal Protease Involved in Kindling Epileptogenesis", The Journal of Biological Chemistry (1999); 274(7): 4220-4224
	Komai et al., "Neuropsin regulates an early phase of Schaffer-collateral long-term potentiation in the murine hippocampus", European Journal of Neuroscience (2000); 12: 1479-1486
	Luo et al., "Human Kallikrein 10: a novel tumor marker for ovarian carcinoma?", Clinica Chimica Acta (2001); 306: 111-118
	Luo et al., "Immunofluorometric Assay of Human Kallikrein 10 and Its Identification in Biological Fluids and Tissues", Clinical Chemistry (2001); 47(2): 237-246
	Magklara et al., "The Human KLK8 (Neuropsin/Ovasin) Gene: Identification of Two Novel Splice Variants and its Prognostic Value in Ovarian Cancer", Clinical Cancer Research (2001); 7: 806-811
	Mitsui et al., "A novel form of human neuropsin, a brain-related serine protease, is generated by alternative splicing and is expressed preferentially in human adult brain", European Journal of Biochemistry (1999); 260: 627-634
	Momota et al., "Blockade of neuropsin, a serine protease, ameliorates kindling epilepsy", European Journal of Neuroscience (1998); 10: 760-764
	Petraki et al., "The Spectrum of Human Kallikrein 6 (Zyme/Protease M/Neurosin Expression in Human Tissues as Assessed by Immunohistochemistry", The Journal of Histochemistry and Cytochemistry (2001); 48(11): 1431-1441
	Shimizu et al., "Characterization of Recombinant and Brain Neuropsin, a Plasticity-related Serine Protease", The Journal of Biological Chemistry (1998); 273(18): 11189-11196
	Shimizu-Okabe et al., "Expression of the kallikrein gene family in normal and Alzheimer's disease brain", Molecular Neuroscience (2001); 12(12): 2747-2751
	Stamey et al., "Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate", The New England Journal of Medicine (1987); 317(15): 909-914
	Stenman et al., "A Complex between Prostate-specific Antigen and α_1 -Antichymotrypsin Is the Major Form of Prostate-specific Antigen in Serum of Patients with Prostatic Cancer: Assay of the Complex Improves Clinical Sensitivity for Cancer", Cancer Research (1991); 51: 222-226
	Stephan et al., "Molecular Forms of Prostate-specific Antigen and Human Kallikrein 2 as Promising Tools for Early Diagnosis of Prostate Cancer", Cancer Epidemiology, Biomarkers & Prevention (2000); 9: 1133-1147
	Underwood et al., "Cloning of Tumor-associated Differentially Expressed Gene-14, a Novel Serine Protease Overexpressed by Ovarian Cancer", Cancer Research (1999); 59: 4435-4439
	Yoshida et al., "Sequence analysis and expression of human neuropsin cDNA and gene", Gene (1998); 213: 9-16
	Yousef et al., "The New Human Tissue Kallikrein Gene Family: Structure, Function, and Association to Disease", Endocrine Reviews (2001); 22(2): 184-204
	Yousef et al., "The New Kallikrein-like Gene, KLK-L2", The Journal of Biological Chemistry (1999); 274(53): 37511-37516

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

Date Mailed: March 16, 2006

Sheet 3 of 3

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11757.0104USWO	Application Number: 10/510,321
	Applicant: DIAMANDIS et al.	
	Filing Date: May 25, 2005	Group Art Unit: 1645

		Yu et al., "Ultrasensitive Time-Resolved Immunofluorometric Assay of Prostate-Specific Antigen in Serum and Preliminary Clinical Studies", Clinical Chemistry (1993); 39(10); 2108-2114
--	--	---

23552 PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	